Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Type 2 Diabetes Report

Consumer genetics company 23andMe on Sunday launched a Type 2 Diabetes Report that tells customers if they are at risk of developing the disease and the lifestyle changes that could make a positive difference. "The report can help customers learn how their genetics, along with other factors such as their weight, age and lifestyle, may influence the likelihood of developing type 2 diabetes, as well as actions they can take to lower that likelihood," 23andMe said in a blog post.

Unlike the company's other genetic health risk tests, which tell customers if they have specific disease-linked SNPs, the type 2 diabetes test employs a polygenic risk score (PRS) that combines more than 1,000 SNPs in an algorithm. This latest test has not been approved or cleared by the US Food and Drug Administration in contrast to the firm's earlier genetic health risk tests.

23andMe said it developed and validated the PRS using the real-world data of 2.5 million customers who have opted to donate their genetic and phenotypic information to research. In a white paper, the company notes that the type 2 diabetes PRS was developed on variants from genome-wide association studies involving people of European ancestry, and that it trained the score on Europeans and recalibrated for other populations. The data show that the score works best in those of European ancestry and doesn't work as well in African American populations.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.